Antitumor activity of tumor necrosis factor a conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice

Cancer Research

Volumn 58, Issue 2, 1998, Pages 290-295

  Kaneda, Yoshihisa ^a   Yamamoto, Yoko ^a   Kamada, Haruhiko ^a   Tsunoda, Shin Ichi ^a   Tsutsumi, Yasuo ^a   Hirano, Takashi ^b   Mayumi, Tadanori ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATL INST BIOSCI HUM TECHNOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; DIMETHYLMALEIC ACID ANHYDRIDE; PYRAN COPOLYMER; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG CONJUGATION; DRUG POTENCY; DRUG POTENTIATION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; SOLID TUMOR; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; DRUG CARRIERS; FEMALE; FIBROSARCOMA; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MALEIC ANHYDRIDES; MICE; MICE, INBRED BALB C; SARCOMA, EXPERIMENTAL; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA; VINYL COMPOUNDS;

EID: 0031975053     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA, 72: 3666-3670, 1975
2. Jones, E. Y., Stuart, D. I., and Walker, N. P. C. Structure of tumour necrosis factor. Nature (Lond.), 338: 225-228, 1989.
3. Aggarwal, B. B., Kohr, W. J., Hass, P. E., Moffat, B., Spencer, S. A., Henzel, W. J., Bringman, T. S., Nedwin, G. E., Goeddel, D. V., and Harkins, R. N. Human tumor necrosis factor. J. Biol. Chem., 260: 2345-2354, 1985.
4. Pennica, D., and Goeddel, D. V. Cloning and characterization of the genes for human and murine tumor necrosis factors. In: D. R. Webb and D. V. Goeddel (eds.), Lymphokines, Vol. 13, pp. 163-180. Orlando, FL: Academic Press, 1987.
5. Nobuhara, M., Kanamori, T., Ashida, Y., Ogino, H., Horisawa, Y., Nakayama, K., Asami, T., Iketani, M., Noda, K., Andoh, S., and Kurimoto, M. The inhibition of neoplastic cell proliferation with human natural tumor necrosis factor. Jpn. J. Cancer Res., 78: 193-201, 1987.
6. Lewis, M., Tartaglia, L. A., Lee, A., Bennett, G. L., Rice, G. C., Wong, G. H. W., Chen, E. Y., and Goeddel, D. V. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc. Natl. Acad. Sci. USA, 88: 2830-2834, 1991.
7. Manda, T., Shimomura, K., Mukumoto, S., Kobayashi, K., Mizota, T., Hirai, O., Matsumoto, S., Oku, T., Nishigaki, F., Mori, J., and Kikuchi, H. Recombinant human tumor necrosis factor-α: evidence of an indirect mode of antitumor activity. Cancer Res., 47: 3707-3711, 1987.
8. Watanabe, N., Niitsu, Y., Umeno, H., Kuriyama, H., Neda, H., Yamauchi, N., Maeda, M., and Urushizaki, I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res., 48: 2179-2183, 1988.
9. Haranaka, K., Satomi, N., and Sakurai, A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int. J. Cancer, 34: 263-267, 1984.
10. Helson, L., Helson, C., and Green, S. Effects of murine tumor necrosis factor on heterotransplanted human tumors. Exp. Cell Biol., 47: 53-60, 1979.
11. Sohmura, Y., Nakata, K., Yoshida, H., Kashimoto, S., Matsui, Y., and Furuichi, H. Recombinant human tumor necrosis factor-II. Antitumor effect on murine and human tumors transplanted in mice. Int. J. Immunopharmacol., 8: 357-368, 1986.
12. Creaven, P. J., Plager, J. E., Dupere, S., Huben, R. P., Takita, H., Mittelman, A., and Proefrock, A. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother. Pharmacol., 20: 137-144, 1987.
13. Blick, M., Sherwin, S. A., Rosenblum, M., and Gutterman, J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res., 47: 2986-2989, 1987.
14. Kimura, K., Taguchi, T., Urushizaki, I., Ohno, R., Abe, O., Furue, H., Hattori, T., Ichihashi, H., Inoguchi, K., Majima, H., Niitani, H., Ota, K., Saito, T., Suga, S., Suzuoki, Y., Wakui, A., Yamada, K., and the A-TNF Cooperative Study Group. Phase I study of recombinant human tumor necrosis factor. Cancer Chemother. Pharmacol., 20: 223-229, 1987.
15. Abuchowski, A., Es, T. V., Palczuk, N. C., and Davis, F. F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem., 252: 3578-3581, 1977.
16. Pyatak, P. S., Abuchowski, A., and Davis, F. F. Preparation of polyethylene glycol: superoxide dismutase adduct, and an examination of its blood circulating life and anti-inflammatory activity. Res. Commun. Chem. Pathol. Pharmacol., 29: 113-127, 1980.
17. Kaneda, Y., Yamamoto, S., Kihira, T., Tsutsumi, Y., Nakagawa, S., Miyake, M., Kawasaki, K., Mayumi, T. Synthetic cell-adhesive laminin peptide YIGSR conjugated with polyethylene glycol has improved antimetastatic activity due to a longer half-life in blood. Inv. Metastasis, 15: 156-162, 1995.
18. Ashihara, Y., Kono, T., Yamazaki, S., and Inada, Y. Modification of E. coli L-asparaginase with polyethylene glycol: disappearance of binding ability to anti-asparaginase serum. Biochem. Biophys. Res. Commun., 83: 385-391, 1978.
19. Katre, N. V., Knauf, M. J., and Laird, W. J. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth-A sarcoma model. Proc. Natl. Acad. Sci. USA, 84: 1487-1491, 1987.
20. Hershfield, M. S. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin. Immunol. Immunopathol., 76: 228-232, 1995.
21. Maeda, H., Matsumoto, T., Konno, T., Iwai, K., and Ueda, M. Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on SMANCS. J. Protein Chem., 3: 181-193, 1984.
22. Konno, T. Targeting chemotherapy for hepatoma: arterial administration of antitumor drugs dissolved in lipiodol. Eur. J. Cancer, 28: 403-409, 1992.
23. Morahan, P. S., Munson, J. A., Baird, L. G., Kaplan, A. M., and Regelson, W. Antitumor action of pyran copolymer and tilorone against Lewis lung carcinoma and B-16 melanoma. Cancer Res., 34: 506-511, 1974.
24. Djeu, J. Y., Heinbaugh, J. A., Holden, H. T., and Herberman, R. B. Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J. Immunol., 122: 175-181, 1979.
25. Harmel, R. P., Jr., and Zbar, B. Tumor suppression by pyran copolymer: correlation with production of cytotoxic macrophages. J. Natl. Cancer Inst., 54: 989-992, 1975.
26. Santoni, A., Puccetti, P., Riccardi, C., Herberman, R. B., Bonmassar, E. Augmentation of natural killer activity by pyran copolymer in mice. Int. J. Cancer, 24: 656-661, 1979.
27. Rinehart, J. J., Young, D. C., and Neidhart, J. A. Evaluation of the immunological and toxicological properties of MVE-2 in Phase I trials. Cancer Res., 43: 2358-2362, 1983.
28. Oda, T., Akaike, T., Hamamoto, T., Suzuki, F., Hirano, T., Maeda, T. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science (Washington DC), 244: 974-976, 1989.
29. Hirano, T., Ohashi, S., Morimoto, S., and Tsuda, K. Synthesis of antitumor-active conjugates of Adriamycin or daunomycin with the copolymer of divinyl ether and maleic anhydride. Makromol. Chem., 187: 2815-2824, 1986.
30. Przybylski, M., Fell, E., Ringsdorf, H., and Zaharko, D. S. Pharmacologically active polymers, 17. Syntheses and characterization of the antitumor agent methotrexate. Makromol. Chem., 179: 1719-1733, 1978.
31. Tsutsumi, Y., Kihira, T., Tsunoda, S., Kanamori, T., Nakagawa, S., and Mayumi, T. Molecular design of hybrid tumour necrosis factor α with polyethylene glycol increases its anti-tumour potency. Br. J. Cancer, 71: 963-968, 1995.
32. Tsutsumi, Y., Tsunoda, S., Kamada, H., Kihira, T., Nakagawa, S., Kaneda, Y., Kanamori, T., and Mayumi, T. Molecular design of hybrid tumour necrosis factor-α II: the molecular size of polyethylene glycol-modified tumour necrosis factor-α affects its anti-tumour potency. Br. J. Cancer, 74: 1090-1095, 1996.
33. Tsutsumi, Y., Kihira, T., Tsunoda, S., Kamada, H., Kanamori, T., Nakagawa, S., Kaneda, Y., and Mayumi, T. Molecular design of hybrid tumor necrosis factor-α III: polyethylene glycol-modified tumor necrosis factor-α markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation. J. Pharmacol. Exp. Ther., 278: 1006-1011, 1996.
34. Inoue, M., Ebashi, I., Watanabe, N., and Morino, Y. Synthesis of a superoxide dismutase derivative that circulates bound to albumin and accumulates in tissues whose pH is decreased. Biochemistry, 28: 6619-6624, 1989.
35. Udenfriend, S., Stein, S., Böhlen, P., and Dairman, W. Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science (Washington DC), 178: 871-872, 1972.
36. Yamazaki, S., Onishi, E., Enami, K., Natori, K., Kohase, M., Sakamoto, H., Tanouchi, M., and Hayashi, H. Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor. Jpn. J. Med. Sci. Biol., 39: 105-118, 1986.
37. Taguchi, T., Abe, S., Nakano, K., Matsui, Y., and Sohmura, Y. Synergistic enhancement of the antitumor activity of recombinant human TNF-α by recombinant human IFN-γ. Cancer Detect. Prev., 12: 105-114, 1988.